BeiGene Competitors
| ONC Stock | 359.05 4.19 1.18% |
BeiGene vs Agilent Technologies Correlation
Good diversification
The correlation between BeiGene and A is -0.03 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding BeiGene and A in the same portfolio, assuming nothing else is changed.
Moving against BeiGene Stock
| 0.74 | DXB | Dimerix Earnings Call This Week | PairCorr |
| 0.66 | VERA | Vera Therapeutics | PairCorr |
| 0.55 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.54 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.52 | DRUG | Bright Minds Biosciences | PairCorr |
BeiGene Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BeiGene and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of BeiGene and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BeiGene does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between BeiGene Stock performing well and BeiGene Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BeiGene's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| HUM | 2.05 | (0.37) | 0.00 | (0.21) | 0.00 | 3.79 | 27.31 | |||
| INSM | 1.85 | (0.34) | 0.00 | 2.72 | 0.00 | 2.84 | 20.19 | |||
| GEHC | 1.48 | 0.12 | 0.07 | 0.14 | 1.64 | 3.38 | 7.77 | |||
| RMD | 1.24 | 0.01 | 0.01 | 0.05 | 1.76 | 2.41 | 9.75 | |||
| IQV | 1.66 | (0.42) | 0.00 | (0.23) | 0.00 | 3.59 | 15.97 | |||
| ALC | 1.12 | 0.02 | 0.01 | 0.06 | 1.11 | 2.60 | 7.05 | |||
| MTD | 1.14 | (0.12) | 0.00 | (0.07) | 0.00 | 2.51 | 7.69 | |||
| NTRA | 1.70 | 0.04 | 0.01 | 0.11 | 2.51 | 3.69 | 14.46 | |||
| PHG | 1.31 | 0.07 | 0.04 | 0.10 | 1.71 | 2.43 | 13.66 | |||
| A | 1.27 | (0.31) | 0.00 | (0.20) | 0.00 | 2.90 | 7.85 |
Cross Equities Net Income Analysis
Compare BeiGene and related stocks such as Humana Inc, Insmed Inc, and GE HealthCare Techno Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INSM | (7.8 M) | (59.7 M) | (41.4 M) | (56.1 M) | (79.2 M) | (118.2 M) | (176.3 M) | (192.6 M) | (324.3 M) | (254.3 M) | (294.1 M) | (434.7 M) | (481.5 M) | (749.6 M) | (913.8 M) | (822.4 M) | (781.3 M) |
| GEHC | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 13.8 B | 2.2 B | 1.9 B | 3.1 B | 2 B | 2.1 B | 3.1 B |
| RMD | 800 K | 254.8 M | 307.1 M | 345.3 M | 352.9 M | 352.4 M | 342.3 M | 315.6 M | 404.6 M | 621.7 M | 474.5 M | 779.4 M | 897.6 M | 1 B | 1.4 B | 1.6 B | 1.7 B |
| IQV | 160.6 M | 241.8 M | 177.5 M | 226.6 M | 356.4 M | 387.2 M | 115 M | 1.3 B | 259 M | 191 M | 279 M | 966 M | 1.1 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B |
| ALC | 931 M | 296.3 M | 296.3 M | 296.3 M | 296.3 M | 296.3 M | (170 M) | 256 M | (227 M) | (656 M) | (531 M) | 376 M | 335 M | 974 M | 1 B | 916.2 M | 962 M |
| MTD | (65.9 M) | 269.5 M | 290.8 M | 306.1 M | 338.2 M | 352.8 M | 384.4 M | 376 M | 512.6 M | 561.1 M | 602.7 M | 769 M | 872.5 M | 788.8 M | 863.1 M | 869.2 M | 912.7 M |
| NTRA | (76.2 M) | (76.2 M) | (76.2 M) | (37.1 M) | (5.2 M) | (70.3 M) | (95.8 M) | (136.3 M) | (128.2 M) | (124.8 M) | (229.7 M) | (471.7 M) | (547.8 M) | (434.8 M) | (190.4 M) | (171.4 M) | (180 M) |
| PHG | 234.6 M | (1.3 B) | 226 M | 1.2 B | 415 M | 645 M | 1.4 B | 1.7 B | 1.1 B | 1.2 B | 1.2 B | 3.3 B | (1.6 B) | (466 M) | (702 M) | 895 M | 881.3 M |
| A | 257 M | 1.2 B | 724 M | 549 M | 401 M | 460 M | 684 M | 316 M | 1.1 B | 719 M | 1.2 B | 1.3 B | 1.2 B | 1.3 B | 1.3 B | 1.5 B | 1.6 B |
BeiGene and related stocks such as Humana Inc, Insmed Inc, and GE HealthCare Techno Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in BeiGene financial statement analysis. It represents the amount of money remaining after all of BeiGene operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.BeiGene Competitive Analysis
The better you understand BeiGene competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BeiGene's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BeiGene's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
BeiGene Competition Performance Charts
Five steps to successful analysis of BeiGene Competition
BeiGene's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BeiGene in relation to its competition. BeiGene's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of BeiGene in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BeiGene's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BeiGene, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your BeiGene position
In addition to having BeiGene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Single Stock ETFs Thematic Idea Now
Single Stock ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Single Stock ETFs theme has 432 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Single Stock ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BeiGene Correlation with its peers. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Will Biotechnology sector continue expanding? Could BeiGene diversify its offerings? Factors like these will boost the valuation of BeiGene. Anticipated expansion of BeiGene directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BeiGene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.5 | Revenue Per Share | Quarterly Revenue Growth 0.41 | Return On Assets | Return On Equity |
Understanding BeiGene requires distinguishing between market price and book value, where the latter reflects BeiGene's accounting equity. The concept of intrinsic value - what BeiGene's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push BeiGene's price substantially above or below its fundamental value.
It's important to distinguish between BeiGene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BeiGene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, BeiGene's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.